The primary objective is to evaluate the virologic efficacy of masitinib plus Best
Supportive Care (BSC), with respect to placebo plus BSC in reducing viral shedding of
SARS-CoV-2 in patients with symptomatic mild to moderate COVID-19.

Patients will be randomized into one of the following treatment groups (all patients will
receive BSC):

1. Masitinib 3.0 mg/kg/day for 10 days versus corresponding placebo

2. Masitinib 3.0 mg/kg/day for 2 days then 4.5 mg/kg/day for 8 days versus
corresponding placebo

3. Masitinib 3.0 mg/kg/day for 2 days then 4.5 mg/kg/day for 2 days then 6.0 mg/kg/day
for 6 days versus corresponding placebo Treatments will be administered for 10 days
and patients will be followed for 1 month. The treatment groups will be compared to
pooled placebo after unblinding.

Regarding Best Supportive Care, for patients with a score of 2 and 3 (ambulatory) on the
10-score WHO clinical progression scale, Best Supportive Care is best available therapy
in the country at the choice of the investigator excluding any antiviral treatment
whether indirect (Ribavirin, Hydroxychloroquine or Chloroquine) or direct
(anti-polymerase or antiprotease, including lopinavir/ritonavir fixed dose combination),
other investigational treatments for SARS-CoV-2, plasma from a person who recovered from
COVID-19, monoclonal antibody therapies and vaccine. For patients with a score of 4 and 5
(hospitalized) on the 10-score WHO clinical progression scale, Best Supportive Care is
dexamethasone.